Latebreakers: Final DEA rule OKs multiple Schedule II Rxs

A number of new, nonopioid osteoarthritis treatment options are either available for patients or in the development pipeline.

Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.

Public health and infectious disease experts offered their perspectives on the 2024 US bird flu outbreak and its potential of becoming a greater public health crisis.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

Systemic lupus erythematosus is associated with a higher risk of cervical dysplasia due to the inflammatory nature of the disease.

NSAIDS are typically the first line of treatment for axial spondyloarthritis.